source
- Novartis and Orionis strike second molecular glue deal for $40M upfrontNovartis is doubling down on its partnership with Orionis Biosciences in a deal worth $40 million upfront and up to $1.4 billion spread across milestones. The Boston and Belgian biotech will ...Endpoints · 1mo ago↗ source
- Sanofi stops immune drug trial in latest research setbackThe failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.BioPharma Dive · 1mo ago↗ source
- SonoThera raises $125M for non-viral gene therapy approachSonoThera has secured $125 million to take its ultrasound-based gene therapy technology into the clinic. The company is focused on two lead programs in Duchenne muscular dystrophy and autosomal dom…